The Current Ratio as of September 2024 (TTM) for Nuvalent, Inc. (NUVL) is 17.44

According to Nuvalent, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 17.44. This represents a change of -7.73% compared to the average of 18.91 of the last 4 quarters.

Nuvalent, Inc. (NUVL) Historical Current Ratio (quarterly & annually)

How has NUVL Current Ratio performed in the past?

The mean historical Current Ratio of Nuvalent, Inc. over the last ten years is 16.73. The current 17.44 Current Ratio has changed 10.33% with respect to the historical average. Over the past ten years (40 quarters), NUVL's Current Ratio was at its highest in in the September 2021 quarter at 44.60. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Nuvalent, Inc. (NUVL) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Nuvalent, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Nuvalent, Inc. (NUVL) Average Current Ratio

How has NUVL Current Ratio performed in the past?

The current Current Ratio of Nuvalent, Inc. (NUVL) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Nuvalent, Inc. (NUVL) Current Ratio vs. Peers

How is NUVL’s Current Ratio compared to its peers?

Nuvalent, Inc.’s Current Ratio is less than DICE Therapeutics, Inc. (0), less than Arcellx, Inc. (25.88), greater than Vaxcyte, Inc. (6.01), less than Viridian Therapeutics, Inc. (17.88), greater than Ventyx Biosciences, Inc. (15.82), greater than Cullinan Oncology, Inc. (14.19), less than Kiniksa Pharmaceuticals, Ltd. (28.87), greater than Replimune Group, Inc. (3.57), greater than Ascendis Pharma A/S (13.46), greater than United Therapeutics Corporation (0.74), greater than Cerevel Therapeutics Holdings, Inc. (4.35), greater than Travere Therapeutics, Inc. (10.22), greater than Structure Therapeutics Inc. (3.04), less than null (41.38),

Build a custom stock screener for Nuvalent, Inc. (NUVL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nuvalent, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Nuvalent, Inc. (NUVL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Nuvalent, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.